Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hexvix®/Cysview®: A Novel, Unique Photodynamic Diagnostic Agent that Improves Lives for Patients with Bladder Cancer Bladder Cancer Background • Bladder cancer epidemiology (US): – 5th most common cancer type – 75,000 new cases in 2012 – 14,680 deaths in 2012 – >560,000 people living with a diagnosis of bladder cancer • 70% of patients are diagnosed with Non-muscle invasive bladder cancer (NMIBC) – 70% Ta – 20% T1 – 5 -10% CIS 2 Medical Need to Improve Bladder Cancer Detection • High risk of Recurrence of NMIBC – Up to 61% at 1 year – Up to 78% at 5 years • Progression to muscle-invasive disease – Up to 17% at 1 year – Up to 45% at 5 years – Common in patients with CIS, which are often difficult to detect • High rate of residual tumor after TURB – 34–76% of patients have evidence of tumor on repeat TURB at 2–6 weeks • Patients with incomplete initial resection are at high risk of recurrence, which may be due to: – Continued growth of microscopic lesions which were not observed at initial TURB – New growth of small residual traces of tumor, often at margins • The highest cost of all cancers 3 – From diagnosis to death per patient ranging from $96,000 - $187,000 in the US Hexvix Blue Light Cystoscopy Diagnosis of NMIBC 4 Hexvix; - See what you have been missing Standard White Light Cystoscopy Hexvix Blue Light Cystoscopy Bladder Cancer in a Different Light Images supplied by Dirk Zaak, MD, University of Munich, Germany 5 Hexvix Body of Clinical Evidence • Hexvix has been extensively studied to investigate improvement in detection of bladder tumors versus white-light cystoscopy – 5 multi-center phase III trials in the USA, Canada and Europe – >1,800 patients with known or suspected bladder cancer • Hexvix cystoscopy: – Significantly improves detection of papillary tumors in 16-29% of patients – Significantly improves detection of patients with CIS tumors by 32% – Detects 96% of all tumors – Improves tumor resection – Significantly reduces tumor recurrence – Results in the more appropriate treatment compared to White Light Cystoscopy 6 Hexvix Diagnostic Improvement Results in Better Outcomes • A clinical trial in 551 patients, demonstrates a significant improvement in both short and long term bladder cancer recurrence free survival – Trend toward less progression and improved bladder preservation • Positive Resource Impact with Hexvix – Hexvix patients cost 15% less over five years as compared to white light patients Total average cost per patient • $30,581 white light , $25,921 Hexvix 7 Hexvix blue-light cystoscopy Hexvix Commercial Success To Date Units Sold, thousands 50 • Patented through 2019+ in most markets 45 • ~230,000 patients diagnosed with Hexvix to date 40 35 • Included in European Urology guidelines as Standard of Care 30 25 • Strict global price €410/$770 20 • Broad reimbursement approval 15 • Market shares range up to 70% 10 • High growth potential ~ 500K procedures annually in US & EU 5 0 2006 2007 2008 2009 2010 2011 2012 8 • Approved in EU and US • 2012: ~35% market share in PHO Nordic territory 6 years after launch Photocure is actively searching for a partner to maximize the commercialization of Hexvix in Selected Territories Territories Available: • Australia • Canada • Latin America • Russia Questions: • Trude Tingvoll Director Business Development & Alliance Management +47 47 45 3313 [email protected] 9